Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1Blood Coagulation Disorders 1Afibrinogenemia 1

Interventions

Specimen Handling 662pembrolizumab 612Magnetic Resonance Spectroscopy 565Carboplatin 451Cisplatin 400Cyclophosphamide 399Biopsy 385Nivolumab 329Paclitaxel 324Gemcitabine 317Radiotherapy 302Bevacizumab 250Dexamethasone 223fludarabine 217Docetaxel 203durvalumab 196Oxaliplatin 189venetoclax 188atezolizumab 188Fluorouracil 178Rituximab 177Pemetrexed 174Capecitabine 172Radiation 171Doxorubicin 168Radiosurgery 161Ipilimumab 149Etoposide 142Leucovorin 141Lenalidomide 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
cryoprecipitate coagulum × 90 days × Clear all
NCT06617897 2026-03-11

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

CSL Behring

Phase 3 Recruiting
90 enrolled

Afibrinogenemia, Blood Coagulation Disorders, Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon âš¡